Status:
COMPLETED
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Lead Sponsor:
GlaxoSmithKline
Conditions:
Mumps
Varicella
Eligibility:
All Genders
11-21 years
Phase:
PHASE3
Brief Summary
This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year...
Detailed Description
Separate injections of the licensed Priorix (MMR vaccine) and Varilrix (chickenpox vaccine) serve as control.
Eligibility Criteria
Inclusion
- A male or female subject between 11-13 months of age (i.e. from 11 month birthday until the day before the 14 month birthday) at the time of the first vaccination.
Exclusion
- History of previous measles, mumps, rubella and/or varicella vaccination or disease, or known exposure to any of these diseases within 30 days prior to the start of the trial
- Planned administration of a vaccine not foreseen by the study protocol from 30 days prior to each vaccination until 42-56 days after each vaccination
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
End Date :
November 1 2005
Estimated Enrollment :
944 Patients enrolled
Trial Details
Trial ID
NCT00127023
Start Date
May 1 2005
End Date
November 1 2005
Last Update
September 21 2016
Active Locations (85)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Bad Saulgau, Baden-Wurttemberg, Germany, 88348
2
GSK Investigational Site
Bönnigheim, Baden-Wurttemberg, Germany, 74357
3
GSK Investigational Site
Bretten, Baden-Wurttemberg, Germany, 75015
4
GSK Investigational Site
Ehingen, Baden-Wurttemberg, Germany, 89584